Merck beats Q3 forecast, cost cuts offset Gardasil decline
October 27, 2014 at 07:18 AM EDT
Oct 27 (Reuters) - Merck & Co reported lower than expected third quarter revenue, hurt by sharply lower sales of its Gardasil vaccine against cervical cancer, but cost cuts enabled the company to beat earnings forecasts.